Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off
As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margins and further debt reduction on a net debt/adjusted EBITDA basis (now 2.8x from 4.0x) demonstrate financial strength in uncertain economic conditions. Robust dividend coverage (2.5x covered by earnings) with steady growth and the strategic streamlining of its portfolio highlights Haleon as a reliable defensive investment.
Haleon buys £170m of shares as Pfizer offloads final stake
Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE). The FTSE 100-listed maker of toothpaste and vitamins paid 385p per share for the off-market purchase, which is part of a previous agreement when Haleon was spun out in 2022 that its former parent companies, GSK being the other, would eventually cut their stakes.
Haleon: Growing Profits And Dividend
I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices.
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025
London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.
Haleon CEO: We're relatively low-exposed to tariffs
Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results
Haleon figures meet expectations; but analysts and investors wanted more
Haleon PLC's (LSE:HLN, NYSE:HLN) prelims have reassured investors, with earnings per share (EPS) beating expectations by 6% in the second half of 2024, according to analysts - although the shares succumbed to a bout of profit taking in their wake. The consumer health giant reported 5% organic growth for the year, slightly ahead of market forecasts, Stifel said.
Haleon plc (HLN) Q4 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN ) Q4 2024 Earnings Conference Call February 27, 2025 4:00 AM ET Company Participants Jo Russell - Head-Investor Relations Brian McNamara - Chief Executive Officer Dawn Allen - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS David Hayes - Jefferies Rashad Kawan - Morgan Stanley Chris Pitcher - Redburn Tom Sykes - Deutsche Bank Jo Russell Good morning, everyone. Welcome to Haleon's Full Year 2024 Q&A call.
Haleon: Investors unimpressed by growth target and £500m buyback as shares slide 3.2%
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.2% in early trading as investors saw little in the results to justify further gains at current valuations. While full-year sales and profits met expectations, analysts noted a lack of clear catalysts.
Haleon results could provide tonic for investor anxiety, says Barclays
When Haleon PLC (LSE:HLN, NYSE:HLN) reports results on Thursday, 27 February, Barclays expects its sales of painkillers to have offset the "well known headwind" from a weak start to the cold and flu season in the final quarter of 2024. Analysts at the bank said that earnings delivery and profit margin expansion are the main areas of focus for investors in the FTSE 100 consumer health products group too, while Futura Medical investors are likely to be keeping an eye out for news on the Eroxon collaboration.
Haleon to invest $54 mln in US R&D centre to boost product innovation
Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.
Haleon: Guidance Implies Uncertainty Around Flu Season
Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3.
Haleon plc (HLN) Q3 2024 Sales Call Transcript
Haleon plc (NYSE:HLN ) Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ET Company Participants Rakesh Patel - Director of Investor Relations Tobias Hestler - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Group AG David Hayes - Jefferies Group LLC Iain Simpson - Barclays Rashad Kawan - Morgan Stanley Celine Pannuti - JPMorgan Chase & Co. Victoria Petrova - BofA Securities Karel Zoete - Kepler Cheuvreux Tom Sykes - Deutsche Bank Rakesh Patel Good morning everyone, and welcome to Haleon's Conference Call for our Third Quarter Trading Statement. I am Rakesh Patel, Director, Investor Relations, and with me today is Tobias Hestler, our CFO.
